Hematology Frontier

The European Hematology Association's 2024 Hybrid Congress is underway in Madrid, bringing together experts and professionals from around the world. From insightful sessions to groundbreaking research, this event is set…

Since 2015, the Chinese Society of Clinical Oncology (CSCO) has been dedicated to presenting annual reports on the progress of clinical oncology in China, under the theme "International Standards, Chinese Characteristics, Learning and Innovation." At the recent "2024 Annual Progress in Chinese Clinical Oncology Conference (BOC) and Best of ASCO 2024 China," the latest "Annual Advances in Chinese Clinical Oncology 2023" report was officially released. At this conference, Dr. Zhitao Ying from the Cancer Institute & Hospital Chinese Academy of Medical Sciences presented a detailed report on the advancements in lymphoma research in China for 2023.

The European Hematology Association (EHA) 2024 has concluded, leaving a trail of impactful insights and advancements in the field of hematology.Highlights included innovative therapies for blood cancers, breakthroughs in stem…

From July 5th to 7th, the 2024 Annual Progress Seminar in Clinical Oncology in China (BOC) and Best of ASCO 2024 China (BOC/BOA 2024) were grandly held in Guangzhou. The conference gathered domestic oncology experts and related professionals to witness the past year's research progress in clinical oncology in China and discuss the future innovative development path of clinical oncology in China. "Oncology Frontier - Hematology Frontier" invited renowned expert in the field of hematologic oncology, Professor Zhixiang Shen from Ruijin Hospital, Shanghai JiaoTong University School of Medicine, for an interview. He introduced major research advancements in hematologic oncology and shared his profound insights on innovation translation and the importance of integrating innovative results into clinical practice.

European Hematology Association (EHA) 2024 has been an incredible journey! Thank you to all the amazing professionals who made it unforgettable. hashtag#EHA2024 hashtag#Hematology hashtag#ConferenceHighlights hashtag#Research

Published on November 5, 2024, in Blood, the double-blind, placebo-controlled PIVOT trial offers new insights into hydroxyurea for HbSC disease, where treatment guidelines remain unclear. Conducted at Korle Bu Teaching…

In recent years, the field of hematologic oncology has seen numerous encouraging breakthroughs, with Chinese scholars increasingly contributing to research in cell therapy, significantly advancing the development of both the discipline and clinical practice. Hematology Frontier specially invited Dr. Ou Bai from The First Bethune Hospital of Jilin University to discuss the progress in the diagnosis and treatment of peripheral T-cell lymphoma (PTCL) in 2024. Dr. Ou Bai shared the groundbreaking advancements in PTCL treatment this year, provided insights into the innovative explorations at their hospital, and offered a forward-looking perspective on new methods and drugs in PTCL therapy.

The curtains have closed on another enlightening EHA Congress, a beacon of innovation in hematology. This year's gathering was a testament to the relentless pursuit of medical advancement, with a…

On August 19th, we honor the incredible dedication and compassion of doctors who work tirelessly to safeguard our health. Let's take a moment to appreciate their unwavering commitment to preserving…

In the vast river of life, blood flows like an unceasing stream, nourishing every inch of land and supporting the vitality and vigor of every life. Anemia, a seemingly inconspicuous…